Mesoblast Limited
Mesoblast Limited (MEOBF) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
meobf · stock forecast · 9 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 9 Wall Street analysts in the past 3 months
Hold
9 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $1.55
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $1.54 | ↓ 0.33% |
1-day model range: $1.54–$1.55. Peak: $1.55 (-0.33%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · MEOBF · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-09-20 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2023-08-30 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2023-08-30 | Jefferies | Upgrade ↑ | Hold→Buy |
| 2023-08-06 | Maxim Group | Downgrade ↓ | Buy→Hold |
| 2023-08-03 | Chardan Capital | Maintains | Sell→Sell |
| 2023-08-03 | William Blair | Downgrade ↓ | Outperform→Market Perform |
| 2023-08-03 | Piper Sandler | Downgrade ↓ | Overweight→Neutral |
| 2023-05-29 | Chardan Capital | Maintains | Sell→Sell |
| 2022-12-05 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2022-06-02 | Chardan Capital | Maintains | Sell→Sell |
Wall Street analysts have recently issued updated ratings on Mesoblast Limited (MEOBF) stock. Of the recent 21 rating actions, 2 were upgrades and 10 were downgrades. 9 analysts currently cover MEOBF.
Analyst Recommendation Trends
MEOBF analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$123M
↓ 59.2% YoY
Revenue Next Year
$200M
↑ 61.9% YoY
EPS This Year
$-0.03
EPS Next Year
$0.01
↓ 119.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast MEOBF EPS of $-0.03 for the current fiscal year, based on estimates from 1 analysts. The MEOBF revenue forecast is $123M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The MEOBF stock forecast is supported by two independent data sources: analyst consensus ratings from 9 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus MEOBF price target is $0.00 (+0.0% upside), with an analyst consensus of Hold.
The MEOBF short-term stock prediction for tomorrow is $1.54 (-0.33%).
Mesoblast Limited trades on OTC under the ticker MEOBF. The MEOBF stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 33% of covering analysts.
Frequently asked questions
MEOBF forecast · 8 questionsAccording to 9 Wall Street analysts, the average 12-month MEOBF price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $1.55.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.